Aim The aim of this study was to assess the risk of adverse drug reactions (ADR s) with
botulinum neurotoxin type A (Bo NT‐A) in children with cerebral palsy (CP) using the World …

This retrospective study aimed to examine the safety of botulinum toxin A (BoNT-A)
treatment in a paediatric multidisciplinary cerebral palsy clinic. In a sample of 454 patients …

Aim To identify factors that increase the likelihood of systemic adverse events after
botulinum neurotoxin A (Bo NT‐A) injections in children with cerebral palsy (CP). Method A …

Aim The aim of this study was to assess changes in health status before and after, as well as
adverse events after, botulinum toxin type A (BoNT‐A) injections in children with cerebral …

Aim We studied the incidence of incontinence and respiratory events in children with
cerebral palsy who received injections of botulinum toxin A (BoNT‐A). Method We used …

Aim To determine the incidence of common adverse events after botulinum toxin A (Bo NT‐
A) injections in children with cerebral palsy (CP) and to identify whether the severity of CP …

In January 2008, the Public Citizen's Health Research Group (a Washington, DC-based
consumer advocacy group) petitioned the US Food and Drug Administration (FDA) to order …

Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral
palsy (CP) have been used for about two decades. The treatment is considered safe but a …

Over the last several years, botulinum toxin type A has gained widespread use for the
management of focal spasticity in children with cerebral palsy. To assess the current …

Objective: To assess the safety of botulinum toxin type A for children with cerebral palsy
using data from randomized clinical trials. Data sources: A search was conducted of …